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Human cytomegalovirus (HCMV) infection, including primary infection resulting from transmission from a
seropositive donor to a seronegative recipient (Dþ/R), remains a signiﬁcant problem in the setting of pe-
ripheral blood stem cell transplantation (PBSCT). The lack of a suitable animal model for studying HCMV
transmission after PBSCT is a major barrier to understanding this process and, consequently, developing novel
interventions to prevent HCMV infection. Our previous work demonstrated that human CD34þ progenitor cell
eengrafted NOD-scid IL2Rgcnull (NSG) mice support latent HCMV infection after direct inoculation and reac-
tivation after treatment with granulocyte colony-stimulating factor. To more accurately recapitulate HCMV
infection in the Dþ/R PBSCT setting, granulocyte colony-stimulating factoremobilized peripheral blood stem
cells from seropositive donors were used to engraft NSG mice. All recipient mice demonstrated evidence of
HCMV infection in liver, spleen, and bone marrow. These ﬁndings validate the NSG mouse model for studying
HCMV transmission during PBSCT.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Despite advances in diagnostics and therapeutics, human
cytomegalovirus (HCMV) remains a signiﬁcant cause of
morbidity andmortality after peripheral blood stem cell (PBSC)
transplantation (PBSCT), and novel approaches to preventing
HCMV infection are needed [1]. HCMV-seronegative recipients
(R) of allografts from HCMV-seropositive donors (Dþ),
although at lower risk for developing HCMV infection and
disease than seropositive recipients (Rþ), will still develop
post-transplantation primary infection in up to 20% of cases
[2-7]. The donor graft is the most important source of virus
early in the post-transplantation period, and a retrospective
analysis of Dþ/R transplantations identiﬁed several factors
associatedwith successful virus transmission [5]. However, the
strict species speciﬁcity of cytomegaloviruses and the conse-
quent lack of a suitable animal model system have hinderedthe experimental validation of these ﬁndings as well as the
development of preventative strategies in this population.
“Humanized” mice, which have undergone trans-
plantation with human cells and/or tissues, have recently
been developed as tools to aid the in vivo study of pathogens
with strict human tropism [8]. We reported the ﬁrst hu-
manized mouse model of HCMV infection in which human
CD34þ hematopoietic progenitor celleengrafted NOD-scid
IL2Rgc
null (NSG) mice directly infected with HCMV supported
latent viral infection, reactivation in human macrophages,
and dissemination after granulocyte colony-stimulating
factor (G-CSF)-induced mobilization of bone marrow he-
matopoietic cells [9]. The present study was carried out to
determine whether NSG mice would also demonstrate
evidence of HCMV infection after transplantation of G-
CSFemobilized PBSCs from HCMV-seropositive donors,
thereby recapitulating Dþ/R PBSCT and validating the NSG
mouse model as a tool for studying HCMV transmission and
infection in this setting.METHODS
Mice
NSG mice were maintained in an speciﬁc pathogen-free facility accord-
ing to procedures approved by Oregon Health and Science University’s
Institutional Animal Care and Use Committee. Before transplantation, mice
Figure 1. Engraftment of NSG mice after transplantation of G-CSFemobilized PBSCs. (A) Representative donor lineage analysis in xenografts. Flow cytometry of
splenocytes from a mouse undergoing transplantation with PBSCs from donor 2 is shown. (B-D) Peripheral blood (B), bone marrow (C), and splenocytes (D) frommice
undergoing transplantation with PBSCs from donors 2, 3, and 4 were analyzed at the time of tissue harvest for engraftment of human cell populations. Donor 1
human CD45þ engraftment was <0.5% in all mice.
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Table 1
Evidence of HCMV Infection in NSG Mice after PBSCT from HCMV-
Seropositive Donors
Donor/Recipient Viral Load*
Bone Marrow Liver Spleen
Donor 1
1 13,130 2060 1455
2 110,991 9350 8322
3 24,243 696 2355
4 11,162 16,809 612
Average 39,881 7229 3186
Donor 2
1 18,443 419 214
2 951 1013 2574
3 25,252 2100 9029
4 1170 2627 544
Average 11,454 1540 3090
Donor 3
1 513 1240 167
2 3039 352 92
3 2741 539 349
4 863 2351 305
Average 1789 1121 228
Donor 4y
1 141 121 0
2 106 185 0
3 134 46 100
Average 127 118 33
* HCMV genomic copies per mg of DNA.
y HCMV-seronegative donor.
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irradiator (JL Shepherd Associates, San Fernando, CA) or a Rad Source RS
2000 X-ray irradiator (Rad Source Technologies, Suwanee, GA). After trans-
plantation, adult micewere providedwith antibiotic water (1.1 g/L neomycin
sulfate and 167 mg/L polymyxin B) up to the time of tissue harvest.
Human Donor Cell Transplantation
G-CSFemobilized PBSCs were obtained from 4 donors after informed
consent in accordance with Oregon Health and Science University Institu-
tional Review Board policies. PBSCs were transplanted i.v. into the retro-
orbital plexus of 8- to 12-wk-old NSG mice. Mice were sacriﬁced at 6-8
wk after transplantation or sooner if they appeared sick. Peripheral blood,
bone marrow, liver, and spleen were collected at the time of euthanasia.
Peripheral blood, bone marrow, and a portion of the spleen were processed
immediately after euthanasia to obtain leukocytes for ﬂow cytometry. Por-
tions of each liver and spleen were placed in RNAlater (Life Technologies,
Grand Island, NY) for preservation until processing for DNA. Human cell
engraftment was assessed by ﬂow cytometry analysis of adult mouse pe-
ripheral blood as described previously [9].
Quantiﬁcation of HCMV Genomic DNA
Total DNA was extracted from tissue or isolated cells with DNAzol (Life
Technologies) following the manufacturer’s suggested protocol, with the
addition of a second DNA precipitation to remove any residual contamina-
tion. In brief, 0.025 g of tissue was placed in an Eppendorf tube containing
1 mL of DNAzol reagent with 1-mm glass beads. The samples were ho-
mogenized for 3 minutes in a BeadBeater (Precellys 24, Bertin Technologies,
Rockville, MD) tissue homogenizer. Total DNA was precipitated by the
addition of 100% ethanol (EtOH), followed by centrifugation at 16,000 g for
10 min. The resulting DNA pellet was washed twice with 75% EtOH, resus-
pended in distilled water, and precipitated a second time with the addition
of sodium acetate and EtOH.
DNA was analyzed by quantitative real-time polymerase chain reaction
(RT-PCR) using a primer and probe set directed against the HCMV US28 gene
sequence: probe, TGATCC CGC TCAGTGT; forward primer, GAACTC ATG CTC
GGT GCT TTC; reverse primer, CTT TGT GGC GCG ACT GAG A. This primer/
probe set was identiﬁed using Primer Express software (Applied Biosystems,
Wilmington, DE). RT-PCR reactions were performed using Fast Advanced
Master Mix (Applied Biosystems) under the following reaction conditions:
thermal activation of AmpliTaq Gold (20 s at 95C), followed by a total of 40
cycles of PCR (1 s at 95C and 20 s at 60C) using the ABI Prism Step One Plus
sequence detection system (Applied Biosystems). PCR results were analyzed
using ABI Prism Step One sequence detection software. HCMV bacterial
artiﬁcial chromosomal DNA served as a quantiﬁcation standard. The sensi-
tivity of detection of this assay wasw50 HCMV genomic copies.RESULTS AND DISCUSSION
The objective of this study was to determine whether
transplantation of G-CSFemobilized PBSCs from HCMV-
seropositive donors would result in successful infection of
recipient NSG mice, similar to what occurs during trans-
plantation of allografts from HCMV-seropositive donors to
-seronegative recipients [5]. Archived G-CSFemobilized
PBSCs from 3 different HCMV-seropositive donors (donors
1-3) were transplanted into a total of 12 sublethally irra-
diated NSG mice (4 mice per donor). As controls, 3 NSG
mice underwent transplantation with G-CSFemobilized
PBSCs from an HCMV-seronegative donor (donor 4). All
mice received approximately 2  106 unfractionated cells
i.v. and were evaluated for overall health daily after
transplantation.
The cohort of mice that received PBSCs from donor 1were
sacriﬁced at 1 wk after transplantation as they began to
appear sickly, with weight loss and loss of normal fur,
consistent with xenogenic graft-versus host disease (GVHD).
Mice that received PBSCs from donors 2, 3, and 4 appeared
well until the planned harvest at 6, 8, and 6 wk after trans-
plantation, respectively. Peripheral blood, spleen, and bone
marrow from eachmouse (except donor 1) were analyzed for
engraftment by ﬂow cytometry and for HCMV DNA by
quantitative RT-PCR.
At the time of harvest at 6-8 wk after transplantation,
mice that received PBSCs from donors 2-4 displayed signiﬁ-
cant levels of human CD45þ cells in the peripheral blood
(mean, 5.5%  5.5%), bone marrow (mean, 12.6%  21.2%),
and spleen (mean, 17.3%  29.3%) (Figure 1). Although the
majority of engrafted human CD45þ cells were either CD3þ T
cells or CD19þ B cells, signiﬁcant numbers of CD14-
expressing myelomonocytic cells were detected as well
(mean, 8%  14% for peripheral blood, 6.3%  7.8% for bone
marrow, and 5.1%  10.2% for spleen).
QuantitativeRT-PCR forHCMVDNAperformedonsamples
obtained from mice that underwent PBSCT from HCMV-
seronegative donor 4 yielded low-level positive results, with
a mean range of 33-127 copies/cell in the bone marrow, liver,
and spleen (Table 1). These results likely reﬂect some degree
of nonspeciﬁc ampliﬁcation of either human or, less likely,
mouse DNA. Using the maximum quantity of HCMV detected
in any sample in the cohort ofmice undergoingPBSCT froman
HCMV-seronegative donor 4 (185 copies/mg of DNA) as a
baseline, 11 of 12 NSGmice that underwent PBSCT from the 3
seropositive donors had virus detected at >10-fold above
baseline levels in bone marrow, liver, and spleen. Given that
HCMV will not replicate in these native mouse tissues, this
ﬁnding most likely reﬂects the detection of disseminated
HCMVpresent in cells derived fromtransplantedhumanPBSC
product. RT-PCR assays without template performed with
each PCR runwere consistently negative (0 copies), indicating
that the results obtained could not not be attributed to cross-
contaminationwithHCMVDNA.QuantitativeRT-PCRanalysis
of HCMV DNA present in total stem cell product from each
donorbefore transplantationwasunsuccessful, likelybecause
of the extremely low levels of virus present [10].
Based on our results, we conclude that G-CSFemobilized
PBSCs obtained from HCMV- seropositive donors represent a
source of infectious virus that is capable of transmission and
dissemination in the NSG mice model. This work comple-
ments and expands on previous studies using NSGmice as an
in vivo model of HCMV latency and reactivation [9]. This
model can be applied to determine the cellular reservoir of
latent virus in PBSCs that is necessary and sufﬁcient for
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of standard cell separation techniques to enrich or deplete
the stem cell product of speciﬁc cell types before trans-
plantation into NSG hosts. Of particular interest are myeloid
lineage cells, such as CD34þ progenitor cells and CD14þ
monocytes, which have been previously described as
harboring latent HCMV [11]. Deﬁning the cell populations
that harbor latent HCMV may lead to novel strategies to
prevent transmission during PBSCT.
Why only 15%-20% of seropositive donors successfully
transmit HCMV to seronegative recipients is not clear. The
previous lackof an experimentalmodel limited the analysis of
transmission to retrospective clinical studies. The NSGmouse
model now permits the experimental evaluation of factors
inherent to the allograft that have been found to correlate
with transmission in such studies [5]. In addition, this model
provides a tool for testing novel hypotheses, such as whether
the risk of transmission is related to the quantitative viral load
in the allograft. Thus, theNSGmousemodel provides a unique
opportunity to gain further insight into the fundamental
mechanisms of HCMV transmission and latency after PBSCT.
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We report the long-term results of a prospective randomized study on the use of ursodeoxycholic acid
(UDCA) for prevention of hepatic complications after allogeneic stem cell transplantation. Two hundred
forty-two patients, 232 with malignant disease, were randomized to receive (n ¼ 123) or not to receive
(n ¼ 119) UDCA from the beginning of the conditioning until 90 days post-transplantation. The results were
reported after 1-year follow-up. UDCA administration reduced signiﬁcantly the proportion of patients
developing high serum bilirubin levels as well as the incidence of severe acute graft-versus-host disease
(GVHD), liver GVHD, and intestinal GVHD. In the UDCA prophylaxis group, nonrelapse mortality (NRM) was
lower and overall survival better than in the control group. After a 10-year follow-up, the difference in the
survival and NRM in favor of the UDCA-treated group, seen at 1 year, was maintained (survival 48% versus
38%, P ¼ .037; NRM 28% versus 41%, P ¼ .01). A landmark analysis in patients surviving at 1 year post-
transplantation showed no signiﬁcant differences between the study groups in the long-term follow-up
